CGTLive’s Weekly Rewind – December 22, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Excision Seeks to Suppress HIV Viral Replication With EBT-101 CRISPR Gene Therapy

The company has released positive safety data from the first 3 participants with HIV-1 so far, with no evidence of vector shedding in sexual organ tissue.

2. Franck Morschhauser, MD, PhD, on Next Steps for Follicular Lymphoma and Liso-Cel

The professor of hematology at University of Lille and chair of LYSA also discussed what the group will be focusing on in 2024.

3. Gene-Edited Cell Therapy Improves Sickle Cell, Transfusion-Dependent Thalassemia Phenotypes

Rabi Hanna, MD, presented updated data from the RUBY and EdiThal trials at ASH 2023.

4. Veit Bücklein, Dr Med, on CAR-T Outcomes Between Male and Female Patients With LBCL

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed the need for research into how CAR T-cells act differently between sexes.

5. More Work Will Be Needed to Harness the Full Potential of Patient Reported Outcomes Measurements

Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital, also gave his thoughts on the recent FDA approval of Vertex and CRISPR’s exa-cel for sickle cell disease.